Ericherrmann

Marc Beer Will Serve As LumeNXT’s Chairman of the Board

On April 2, 2019, LumeNXT made it official publicly that Marc Beer, a pharmaceuticals executive with tremendous success in the guiding pharmaceuticals companies to towards great success and prosperity, will serve LumeNXT in the role of Chairman of the Board. LumeNXT specializes in the niche of producing surgical devices for the medical field. It is currently pioneering the utilization of intracavity LED illumination for use in minimally invasive surgical procedures. LumeNXT’s state-of-the-art illumination platform has the utility of enhancing workflow efficiency, precision, and safety by improving visualization during surgical procedures. The field of surgical illumination has made substantial advancement as a result of the advent of LumeNXT’s unique proprietary illumination technology. Paul Rhyne, LumeNXT’ co-founder, is extremely excited with Marc Beer’s appointment to LumeNXT’s Chairman of the Board position, citing that “Marc has demonstrated high levels of success in multiple startup companies that he’s guided through the multiple growth phases,” and “His vast experience in starting companies and guiding them through global commercial rollout and the path to profitability is highly valued as our company grows.”

Marc Beer is an extraordinarily successful pharmaceuticals executive who has for more than 25 years been devoting his career to the development and commercialization of various products and compounds for the biopharmaceutical field, including biotechnology, pharmaceuticals diagnostics, and devices. He obtained a formal university education from Miami University in Ohio. During his greater than 25 years in the biopharmaceutical field, Marc Beer has founded and successfully ran a good number of biopharmaceutical companies. In August 2016, he founded Renovia, Inc., a women’s health startup company located in Boston, ran the company as its chief executive officer. Marc Beer successful raised $42 million for Renovia, Inc., to advance the company’s mission of developing and providing digital therapeutic and diagnostic devices to the more than 250 million women afflicted with pelvic floor disorders, such as pelvic organ prolapse, urinary incontinence, and fecal incontinence. In April of 2000, he founded ViaCell for the purpose of developing and facilitating the use of umbilical cord blood stem cells to treat a number of different diseases. Marc Beer so successfully guided ViaCell that the company went public in 2005. Marc Beer also founded Minerva Neurosciences Inc., a biopharmaceutical company that conducts clinical trials and has had much success in developing a portfolio of viable products to treat central nervous system diseases. Minerva is also developing highly innovative therapeutic compounds with the potential to treats mood disorders, insomnia, schizophrenia, major depressive disorders, and Parkinson’s Disease. Another biopharmaceutical company that was founded by Mark Beer is Good Start Genetics, Inc. where he is both chairman of the board of directors and chairman of the compensation committee. Learn more: https://blogwebpedia.com/marc-beer-entrepreneurial-spirit-biotech.html#.XHg3cFNKiqQ

Scroll To Top